{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968515",
  "id": "02968515",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250711",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250711/pdf/06lq1p1mfmmkvx.pdf",
  "summary": "- **Board Change**: Appointment of Dr. Thomas Duthy as Non-Executive Director (effective 11 July 2025), replacing Dr. Gabriel Liberatore (resigned for personal reasons).  \n- **Director Alignment**: Dr. Duthy to receive shares at $1.50 (25% premium to recent capital raising price) in lieu of first-year fees, with 12-month voluntary escrow.  \n- **Background**: Dr. Duthy brings healthcare/life sciences expertise, including prior role in Sirtex Medical\u2019s $1.9bn acquisition.  \n\n*No material financial, operational, or trading impact identified.*",
  "usage": {
    "prompt_tokens": 1599,
    "completion_tokens": 131,
    "total_tokens": 1730,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T23:50:10.058869"
}